List of Fulvestrant drug patents

Fulvestrant is owned by Fresenius Kabi Usa.

Fulvestrant contains Fulvestrant.

Fulvestrant has a total of 3 drug patents out of which 0 drug patents have expired.

Fulvestrant was authorised for market use on 20 May, 2019.

Fulvestrant is available in solution;intramuscular dosage forms.

Fulvestrant can be used as treatment of hormone receptor positive advanced breast cancer in postmenopausal women.

The generics of Fulvestrant are possible to be released after 17 May, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in